Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Ipilimumab in Metastatic Renal Cell Carcinoma: NCT06399419 Clinical Landscape Report 2026
9 min read
Ipilimumab in Metastatic Renal Cell Carcinoma: NCT06399419 Clinical Landscape Report 2026
16 October 2026
NCT06399419 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
SM-020 in Keratosis, Seborrheic: NCT06409195 Clinical Landscape Report 2026
9 min read
SM-020 in Keratosis, Seborrheic: NCT06409195 Clinical Landscape Report 2026
16 October 2026
NCT06409195 clinical landscape for Keratosis, Seborrheic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Voclosporin in Lupus Nephritis: NCT06406205 Clinical Landscape Report 2026
9 min read
Voclosporin in Lupus Nephritis: NCT06406205 Clinical Landscape Report 2026
16 October 2026
NCT06406205 clinical landscape for Lupus Nephritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Ianalumab in Sjogren's Syndrome: NCT06411639 Clinical Landscape Report 2026
9 min read
Ianalumab in Sjogren's Syndrome: NCT06411639 Clinical Landscape Report 2026
16 October 2026
NCT06411639 clinical landscape for Sjogren's Syndrome: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Albumin-Bound Paclitaxel in TP-53 Mutated Endometrial Carcinoma: NCT06413992 Clinical Landscape Report 2026
9 min read
Albumin-Bound Paclitaxel in TP-53 Mutated Endometrial Carcinoma: NCT06413992 Clinical Landscape Report 2026
16 October 2026
NCT06413992 clinical landscape for TP-53 Mutated Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white s…
Read →
Belimumab in Systemic Lupus Erythematosus: NCT06411249 Clinical Landscape Report 2026
9 min read
Belimumab in Systemic Lupus Erythematosus: NCT06411249 Clinical Landscape Report 2026
16 October 2026
NCT06411249 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
NK-042 in Female Genital Neoplasms: NCT06415500 Clinical Landscape Report 2026
9 min read
NK-042 in Female Genital Neoplasms: NCT06415500 Clinical Landscape Report 2026
16 October 2026
NCT06415500 clinical landscape for Female Genital Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
UTAA09/17 in Idiopathic Inflammatory Myopathies: NCT06417398 Clinical Landscape Report 2026
9 min read
UTAA09/17 in Idiopathic Inflammatory Myopathies: NCT06417398 Clinical Landscape Report 2026
16 October 2026
NCT06417398 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
Read →
Megestrol Acetate in Endometrial Endometrioid Adenocarcinoma: NCT06417736 Clinical Landscape Report 2026
9 min read
Megestrol Acetate in Endometrial Endometrioid Adenocarcinoma: NCT06417736 Clinical Landscape Report 2026
16 October 2026
NCT06417736 clinical landscape for Endometrial Endometrioid Adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
Read →
Belantamab in Autoimmune Diseases: NCT06413511 Clinical Landscape Report 2026
9 min read
Belantamab in Autoimmune Diseases: NCT06413511 Clinical Landscape Report 2026
16 October 2026
NCT06413511 clinical landscape for Autoimmune Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Psilocybin in Endocrine Gland Neoplasms: NCT06416085 Clinical Landscape Report 2026
9 min read
Psilocybin in Endocrine Gland Neoplasms: NCT06416085 Clinical Landscape Report 2026
16 October 2026
NCT06416085 clinical landscape for Endocrine Gland Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
IM-83 (Imunopharm) in Osteosarcoma, Recurrent: NCT06412458 Clinical Landscape Report 2026
9 min read
IM-83 (Imunopharm) in Osteosarcoma, Recurrent: NCT06412458 Clinical Landscape Report 2026
16 October 2026
NCT06412458 clinical landscape for Osteosarcoma, Recurrent: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →